New Heart Failure Treatments Prove Pharma Companies Have Finger on the Pulse

Friday 27 July 2012, Amsterdam

Individuals suffering from Chronic Heart Failure (CHF) can look forward to the appearance of many new drug options over the next few years, and place hope in a cure through future stem cell therapies, according to the new Chronic Heart Failure (CHF) Therapeutics - Pipeline Assessment and Market Forecasts to 2019 report.

The report shows that dissatisfaction with limited CHF therapies, alongside the fast expanding patient population, assures sky-high revenue for pharmaceutical companies willing to develop superior treatments. As a result, numerous molecules are being developed for CHF patients, and stem cell treatment may even offer a cure by transforming the tissue of the heart.

The number of patients seeking treatment for CHF is expected to grow, due to greater health awareness among the general public, increased life expectancy and, consequently, an aging global population, which will be naturally more susceptible to Acute Heart Failure (AHF).

Currently, the only treatment choices for CHF patients are generic drugs, which do not treat the underlying cause of the disease. Drugs such as beta-blockers and diuretics can manage the symptoms of CHF by improving cardiac function, but none can provide disease-modifying mechanisms.

As a result, demand is growing for new treatment options that can present improved safety and efficacy and unique new molecules that can restore or regenerate impaired cardiac muscle cells.

Various pipeline molecules are expected to enter the market within the next few years to provide improved options for CHF patients. This analysis shows that there are 41 molecules under development in the CHF therapeutics pipeline, of which 78% are First-in-Class (FIC) and 25% are in Phase III.

Several molecules are currently being clinically tested for safety and efficacy in improving cardiac function, and many upcoming drugs include novel mechanisms that could well take over as the standard first-in-line therapy for the treatment and management of CHF.

Stem cell therapy is also capable of improving the CHF treatment pattern. Stem cell therapies currently in development hold the potential to restore cardiac muscle function by regenerating and strengthening heart muscle cells. This will transform patient quality of life and fulfill the market need by providing curative therapy.

The global CHF therapeutics market grew at a Compound Annual Growth Rate (CAGR) of 4% from $3,171.3m in 2006 to $3,849.9m in 2011. GlobalData analysis suggests that market will grow at a CAGR of 3.1% during the forecast period, to reach $4,918.4m by 2019.

This report is an essential source of information and analysis on the global Chronic Heart Failure Therapeutics market. It identifies the key trends shaping and driving the market, and provides insights on the prevalent competitive landscape and emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Chronic Heart Failure Therapeutics sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.